136 related articles for article (PubMed ID: 26948535)
1. Presence of type 1 diabetes in women with polycystic ovary syndrome: Does it have any impact on anti-Müllerian hormone concentrations?
Goulis DG
Metabolism; 2016 May; 65(5):812-814. PubMed ID: 26948535
[No Abstract] [Full Text] [Related]
2. Impact of metformin on anti-Müllerian hormone in women with polycystic ovary syndrome: a secondary analysis of a randomized controlled trial.
Madsen HN; Lauszus FF; Trolle B; Ingerslev HJ; Tørring N
Acta Obstet Gynecol Scand; 2015 May; 94(5):547-51. PubMed ID: 25736975
[TBL] [Abstract][Full Text] [Related]
3. Effects of metformin on serum insulin and anti-Mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome.
Nascimento AD; Silva Lara LA; Japur de Sá Rosa-e-Silva AC; Ferriani RA; Reis RM
Gynecol Endocrinol; 2013 Mar; 29(3):246-9. PubMed ID: 23194004
[TBL] [Abstract][Full Text] [Related]
4. Serum anti-Müllerian hormone concentration in women with polycystic ovary syndrome and type 1 diabetes mellitus.
Łebkowska A; Adamska A; Karczewska-Kupczewska M; Nikołajuk A; Otziomek E; Milewski R; Górska M; Wołczyński S; Kowalska I
Metabolism; 2016 May; 65(5):804-811. PubMed ID: 26961579
[TBL] [Abstract][Full Text] [Related]
5. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia.
Panidis D; Georgopoulos NA; Piouka A; Katsikis I; Saltamavros AD; Decavalas G; Diamanti-Kandarakis E
Gynecol Endocrinol; 2011 Aug; 27(8):587-92. PubMed ID: 20836726
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review.
Lautatzis ME; Goulis DG; Vrontakis M
Metabolism; 2013 Nov; 62(11):1522-34. PubMed ID: 23886298
[TBL] [Abstract][Full Text] [Related]
7. A challenge in the management of women with polycystic ovary syndrome.
Seow KM; Lee WL; Wang PH
Taiwan J Obstet Gynecol; 2016 Apr; 55(2):157-8. PubMed ID: 27125394
[No Abstract] [Full Text] [Related]
8. Insulin levels, insulin resistance and the use of metformin in polycystic ovary syndrome.
Hutchison SK; Zoungas S; Teede HJ
Med J Aust; 2007 Mar; 186(5):268-9; author reply 271-2. PubMed ID: 17391092
[No Abstract] [Full Text] [Related]
9. Ovarian reserve in women with Type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study.
Kim C; Dunn RL; Braffett B; Cleary PA; Arends V; Steffes M; Lanham MS; Randolph JF; Wessells H; Wellons MF; Sarma AV;
Diabet Med; 2016 May; 33(5):691-2. PubMed ID: 26798983
[TBL] [Abstract][Full Text] [Related]
10. A case of lean polycystic ovary syndrome with early stage of type 1 diabetes successfully treated with metformin.
Shigiyama F; Kumashiro N; Rikitake T; Usui S; Saegusa M; Kitamura M; Uchino H; Hirose T
Endocr J; 2016; 63(2):193-8. PubMed ID: 26765270
[TBL] [Abstract][Full Text] [Related]
11. The role of anti-Mullerian hormone and inhibin B in the assessment of metformin therapy in women with polycystic ovarian syndrome.
Saleh BO; Ibraheem WF; Ameen NS
Saudi Med J; 2015 May; 36(5):562-7. PubMed ID: 25935176
[TBL] [Abstract][Full Text] [Related]
12. Use of metformin in pediatric age.
Brufani C; Fintini D; Nobili V; Patera PI; Cappa M; Brufani M
Pediatr Diabetes; 2011 Sep; 12(6):580-8. PubMed ID: 21366813
[No Abstract] [Full Text] [Related]
13. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
[TBL] [Abstract][Full Text] [Related]
14. Ovarian markers and irregular menses among women with type 1 diabetes in the Epidemiology of Diabetes Interventions and Complications study.
Kim C; Miller RS; Braffett BH; Pan Y; Arends VL; Saenger AK; Barnie A; Sarma AV;
Clin Endocrinol (Oxf); 2018 Mar; 88(3):453-459. PubMed ID: 29314138
[TBL] [Abstract][Full Text] [Related]
15. Metformin for the treatment of the polycystic ovary syndrome.
Nestler JE
N Engl J Med; 2008 Jan; 358(1):47-54. PubMed ID: 18172174
[No Abstract] [Full Text] [Related]
16. Metformin in polycystic ovary syndrome.
Diamanti-Kandarakis E; Economou F; Palimeri S; Christakou C
Ann N Y Acad Sci; 2010 Sep; 1205():192-8. PubMed ID: 20840272
[TBL] [Abstract][Full Text] [Related]
17. Effect of dose escalation of metformin on clinical features, insulin sensitivity and androgen profile in polycystic ovary syndrome.
Yasmin E; Glanville J; Barth J; Balen AH
Eur J Obstet Gynecol Reprod Biol; 2011 May; 156(1):67-71. PubMed ID: 21277073
[TBL] [Abstract][Full Text] [Related]
18. Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment.
Fleming R; Harborne L; MacLaughlin DT; Ling D; Norman J; Sattar N; Seifer DB
Fertil Steril; 2005 Jan; 83(1):130-6. PubMed ID: 15652898
[TBL] [Abstract][Full Text] [Related]
19. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
Teede HJ; Meyer C; Hutchison SK; Zoungas S; McGrath BP; Moran LJ
Fertil Steril; 2010 Jan; 93(1):184-91. PubMed ID: 19019358
[TBL] [Abstract][Full Text] [Related]
20. Use of metformin in polycystic ovary syndrome.
De Sloover Koch Y; Ernst ME
Ann Pharmacother; 2001 Dec; 35(12):1644-7. PubMed ID: 11793635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
